What We Do
Using the experience gained in decades of activity on the African continent, Marchitalia has created a commercial network that offers the opportunity to access the market of more than 30 countries in the African area with the support of competent local trade organizations, reliable and specialized in the distribution, promotion and registration of pharmaceutical products.
When at the end of the 50’s of the last century, a family of Italian entrepreneurs in the Italian pharmaceutical field decides to invest in the health sector in Africa, internationalization, diversification and above all, access to care for the populations of the most remote areas of the world, were still all in formation concepts to decline.Rooted in the province of Lucca, in Tuscany, in the family…
Marchitalia’s activity is aimed in particular at the following types of products:
Human blood derivatives
- Intravenous immunoglobulins
- Immunoglobulibne specific anti hepatitis, anti D, anti tetanus
- Factor VIII and IX of cogaulation
- Prothrombin complex
Serums for human use
- Anti-tetanus serum
- Scorpion serum
- Rabies serum
Vaccines for human use
- Tetanus vaccine
- Dipto-tetanus vaccine
- Rabies vaccine
With a person dying every 30 seconds from a hepatitis related illness – we can’t wait to act on viral hepatitis.
Rh isoimmunization in Sub-Saharan Africa indicates need for universal access to anti-RhD immunoglobulin and effective management of D-negative pregnancies
AfricaBio is pleased to announce that registration is open for the 5th Annual BIO Africa Convention.
The convention taking place at the Durban ICC, under the theme “Africa Resilient: Life Sciences Innovation For Achieving Health and Food Security”.
ISTH 2022 is the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place in London, England, U.K., from July 9-13, 2022.
Hepatitis B and C place a significant public health burden on the Senegalese population.
Hepatitis B is highly endemic in Senegal. Comparatively, hepatitis C is less endemic but many individuals are still affected. In Senegal, recent studies have assessed the burden of viral hepatitis B and C with a prevalence rate of 8 to 9% for HBV and of 2% for HCV.
The fight against viral hepatitis in Senegal is being led by the National Program Against Hepatitis PNLH.
Did you know? The global pandemic led governments around the world to de-prioritise their hepatitis response as they attempted to…